Help Shape the Future of PDA Management in Extremely Preterm Infants
- Jul 21
- 2 min read
One of the biggest unanswered questions in neonatal medicine is how best to manage hemodynamically significant patent ductus arteriosus (hsPDA) in extremely preterm infants.
Despite decades of research, there remains considerable variation in clinical practice around the world. Some centres favor early treatment, while others adopt a more conservative approach. The timing of intervention, choice of therapy, and criteria for treatment all continue to vary widely.
To better understand current practice and help design the next generation of clinical research, an international group of neonatal investigators is conducting a survey focused on the management of preterm infants born at ≤26+6 weeks' gestation who remain invasively ventilated beyond seven days of age with hsPDA.
Why is this important?
Future clinical trials should answer questions that matter most to clinicians caring for these vulnerable infants every day.
Your experience and perspectives will help:
Understand current international practice.
Identify areas of agreement and variation.
Inform the design of a future multicentre randomized clinical trial.
Improve the quality of evidence guiding PDA management.
Who should participate?
We invite:
Neonatologists
Neonatal fellows
Neonatal nurse practitioners
Pediatric cardiologists involved in PDA management
Clinicians caring for extremely preterm infants
Survey details
🕒 Time required: Approximately 10 minutes
✅ Completely anonymous
✅ Approved by the University of British Columbia Research Ethics Board (H26-01522)
Complete the survey here
If you have any questions, please contact:
Dr. Uthaya Kumaran Kanagaraj📧 uthaya.kanagaraj@cw.bc.ca
Dr. Souvik Mitra📧 souvik.mitra@cw.bc.ca
This survey has been developed with the support of an international collaborative group, including Dr. Gabriel Altit (McGill University) and Dr. Georg Schmölzer (University of Alberta).
Every response will help shape the future of neonatal PDA research.
Thank you for contributing to better evidence—and ultimately better outcomes—for extremely preterm infants.
Comments